We are still transitioning from our old blog, so pardon our dust. To contact the Mesothelioma Applied Research Foundation or for immediate help with your questions, you can reach us by phone at 877.363.6376.
FDA Approves KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Patients with Unresectable or Metastatic Malignant Pleural Mesothelioma
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
